Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults

Background: BRII-196 and BRII-198 are two anti-SARS-CoV-2 monoclonal neutralizing antibodies as a cocktail therapy for treating COVID-19 with a modified Fc region that extends half-life. Methods: Safety, tolerability, pharmacokinetics, and immunogenicity of BRII-196 and BRII-198 were investigated in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Xiaohua, Zhang, Zheng, Ma, Ji, Cheng, Lin, Ji, Yun, Liu, Yang, Zhao, Dong, Zhang, Wen, Li, Chunming, Yan, Li, Margolis, David, Zhu, Qing, Zhang, Yao, Zhang, Fujie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486188/
https://www.ncbi.nlm.nih.gov/pubmed/36147329
http://dx.doi.org/10.3389/fphar.2022.983505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486188/
https://www.ncbi.nlm.nih.gov/pubmed/36147329
http://dx.doi.org/10.3389/fphar.2022.983505

Ejemplares similares